BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ypsomed And Safety Syringes Inc. Announce Collaboration In The Development Of A Reusable Autoinjector For The UltraSafe Drug Delivery System


10/19/2005 5:13:14 PM

BURGDORF, Switzerland & CARLSBAD, Calif.--(BUSINESS WIRE)--April 5, 2005--Ypsomed AG, in collaboration with Safety Syringes Inc., has designed a reusable Autoinjector specifically for use with the UltraSafe(R) Drug Delivery Systems by Safety Syringes Inc. The device will allow flexibility for Pharmaceutical Partners and is intended to ensure that there is no exposure to potential needle stick injuries at any time during or after use and provide additional convenience for self-injecting patients. Ypsomed has designed an Autoinjector that will accommodate the UltraSafe(R) Passive(TM) Delivery System. "Incorporating safety into a drug delivery system has become very important and the UltraSafe device by Safety Syringes Inc. has proven a preferred product by many of our pharmaceutical clients and by the end-user market," commented Matthew Robin, CEO of Ypsomed Holding AG. "We saw this co-development as an important strategic decision to help offer a full range of solutions to our target client base."

Read at BioSpace.com

Ypsomed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES